Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. März 2023 07:58 ET | Quelle: NurExone

NurExone Biologic Reports Additional Positive Preclinical Trial Outcomes with ExoPTEN: 75% of Paralyzed Rats Show Recovery after Acute Spinal Cord Injury Study

TORONTO and TEL AVIV, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Toronto and Tel Aviv, March 20, 2023 - Biopharmaceutical firm NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or...
17. Februar 2023 08:00 ET | Quelle: NurExone

NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug

TORONTO and HAIFA, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy...
13. Februar 2023 08:35 ET | Quelle: NurExone Biologic Inc

NurExone Biologic Inc. Emerges as a Promising Investment Opportunity in Biotechnology

TORONTO and TEL AVIV, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a Toronto-listed biopharmaceutical company, is developing ExoPTEN, a...
16. August 2022 09:43 ET | Quelle: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NRx Pharmaceuticals, Inc. - NRXP; NRXPW

NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP;NRXPW). Such investors...
11. Mai 2022 16:41 ET | Quelle: Lifshitz Law Firm, P.C.

Lifshitz Law PLLC Announces Investigations of CorMedix Inc. (NASDAQGM: CRMD), FirstCash Holdings, Inc. (NASDAQ: FCFS), NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), Renovacare, Inc. (OTC-BB: RCAR)

NEW YORK, May 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQGM: CRMD) Lifshitz Law PLLC announces that a class action complaint was filed against CRMD alleging that Defendants made material...
13. April 2022 15:32 ET | Quelle: Lifshitz Law Firm, P.C.

Lifshitz Law Firm, P.C. Announces Investigations of Clarivate Plc. (NYSE: CLVT), NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), Shattuck Labs, Inc. (NASDAQ: STTK), and Standard Lithium Ltd. (NYSE: SLI)

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Clarivate Plc. (NYSE: CLVT) Lifshitz Law PLLC announces that a class action complaint was filed on behalf of shareholders of Clarivate alleging that...
21. März 2022 10:57 ET | Quelle: The Rosen Law Firm PA

NRXP DEADLINE TODAY: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 21 Deadline in Securities Class Action – NRXP, NRXPW

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP, NRXPW) between...
13. März 2022 16:01 ET | Quelle: Robbins Geller Rudman & Dowd LLP

DEADLINE APPROACHING: Robbins Geller Rudman & Dowd LLP Announces that NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, March 13, 2022 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP; NRXPW) securities between June...
13. März 2022 15:04 ET | Quelle: The Rosen Law Firm PA

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important March 21 Deadline in Securities Class Action – NRXP, NRXPW

NEW YORK, March 13, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP, NRXPW) between...
11. März 2022 14:00 ET | Quelle: Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)

LOS ANGELES, March 11, 2022 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 21, 2022 deadline to file a lead plaintiff motion in the class action...

Vorherige Seite

Nächste Seite